Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections

NCT03710564 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

535

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Age-Related Macular Degeneration

Interventions

BIOLOGICAL: Brolucizumab
BIOLOGICAL: Aflibercept

Sponsor

Novartis Pharmaceuticals